Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Moodys
Mallinckrodt
Boehringer Ingelheim
McKesson

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR ROBINUL FORTE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Robinul Forte

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00579085 ↗ Double Blind Placebo Controlled Study of Outpatient Intravenous Ketamine for the Treatment of CRPS Completed Drexel University College of Medicine Phase 2 2006-09-01 Complex Regional Pain Syndrome is a debilitating and extremely difficult to treat condition. There is a large body of evidence demonstrating the therapeutic value of N-methyl-D-aspartate (NMDA)-receptor antagonists in CRPS. The NMDA antagonist ketamine has been shown to be effective in the treatment of CRPS, resulting in complete remission of the disease in some patients. The purpose of this study is to evaluate intravenous outpatient infusion of sub-anesthetic doses of ketamine for the treatment of CRPS. A thorough evaluation of this procedure, providing information into the degree of relief and which of the constellation of RSD symptoms are best alleviated by this procedure would result in the optimization of this therapy for the treatment of CRPS.
NCT01191398 ↗ Effectiveness of Atropine and Glycopyrrolate to Reduce Hyper Salivation With Ketamine Sedation Completed Craig J. Huang N/A 2010-06-01 The purpose of this study is to determine if the antisialagogues (anti-salivary agents), Atropine and Glycopyrrolate, are effective in reducing hypersalivation when sedating patients with Ketamine for procedural sedation in the emergency department or abscess clinic. The investigators will measure salivary flow rate by collecting oral secretions by oral suctioning over a 30 minute time period starting with the administration of Ketamine. The investigators hypothesize that patients who receive either atropine or glycopyrrolate will have fewer oral secretions than patients who receive placebo.
NCT02872935 ↗ Minimizing Nausea and Vomiting During Spinals for CS Terminated Kokila N Thenuwara Phase 4 2015-05-15 In parturients undergoing Cesarean section under spinal anesthesia, co-loading of 1 liter of crystalloids, with placing the spinal, along with administering a phenylephrine infusion and glycopyrrolate, enables placing a spinal with minimal perioperative nausea and vomiting and good intra and post-operative pain relief.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Robinul Forte

Condition Name

Condition Name for Robinul Forte
Intervention Trials
Spine Deformity 1
Surfactant Deficiency Syndrome Neonatal 1
Abdominal Neoplasm 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Robinul Forte
Intervention Trials
Nausea 1
Neurofibroma 1
Critical Illness 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Robinul Forte

Trials by Country

Trials by Country for Robinul Forte
Location Trials
United States 4
Finland 1
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Robinul Forte
Location Trials
Wisconsin 1
Iowa 1
Texas 1
Pennsylvania 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Robinul Forte

Clinical Trial Phase

Clinical Trial Phase for Robinul Forte
Clinical Trial Phase Trials
Phase 4 3
Phase 2 1
N/A 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Robinul Forte
Clinical Trial Phase Trials
Completed 3
Recruiting 1
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Robinul Forte

Sponsor Name

Sponsor Name for Robinul Forte
Sponsor Trials
McGill University Health Center 1
McGill University Health Centre/Research Institute of the McGill University Health Centre 1
Drexel University College of Medicine 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Robinul Forte
Sponsor Trials
Other 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Harvard Business School
Mallinckrodt
Baxter
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.